Regenerative Cellular Therapy

We offer regenerative therapy using perinatal allograft products derived from perinatal tissue. These biologics are sourced exclusively from healthy, full-term births within the United States. Donors are carefully screened through an extensive medical history review, infectious disease testing, and lifestyle assessment to ensure the highest standards of quality and safety. All tissue is collected with informed consent following delivery. Processing is performed in FDA-registered, AATB-accredited facilities use sterile techniques specifically designed to preserve the native biological properties of the material. The product is minimally manipulated, maintaining compliance with 21 CFR Part 1271, which governs human cells, tissues, and cellular and tissue-based products (HCT/Ps).

Our perinatal-derived allograft is rich in regenerative elements, including growth factors, cytokines, hyaluronic acid, extracellular matrix proteins, and a naturally high population of mesenchymal stem cells (MSCs). While this product is not classified or marketed as a "stem cell therapy," it is important for patients to understand that a robust concentration of native stem cells is present within the biological material, along with other key regenerative components. These naturally occurring MSCs are part of the overall biologic matrix, offering potential support to the body’s natural healing and repair Processes.

Regenerative therapy aims to supplement areas of tissue injury, inflammation, or degeneration by introducing biologically active materials that may enhance the local cellular environment. While this therapy is not FDA-approved to treat, cure, diagnose, or prevent any disease or condition, it is used by trained healthcare professionals to promote structural support and tissue optimization. Individual patient outcomes may vary, and no guarantee of improvement can be made. However, many patients pursuing regenerative therapy report improvements in comfort, function, mobility, and overall quality of life, especially when addressing joint discomfort, soft tissue irritation, or age-related changes.

The mechanisms of action believed to contribute to these outcomes include modulation of inflammation, support of extracellular matrix restoration, and facilitation of cellular communication within targeted tissues. The presence of mesenchymal stem cells within the perinatal tissue adds an important regenerative component, although the therapeutic effects depend on a range of biological, procedural, and patient-specific factors.



Treatment is administered through direct injection of the allograft material into the area of concern, following a full clinical assessment and consultation. As with any medical procedure, regenerative therapy carries risks, including localized discomfort, infection, swelling, allergic response, and the possibility of no clinical improvement. A full discussion of the risks and benefits is a vital part of the informed consent process prior to treatment.